Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease

1. A compound of the general formula (I):

P-E-I  (I)

or a pharmaceutically acceptable salt thereof, wherein

P is a group represented by the general formula (II):

(CH 2 ) n —O—(CH 2 ) k —X  (II)

wherein

n is an integer of from 3 to 8; and

k is 0, 1 or 2;

X represents CH 2 OH, CH 2 OAc, CH(O) or a group selected from the group consisting of:

wherein

R and R′ each independently represents a hydrogen atom; or a C 1 -C 6 alkyl group which may be substituted with one or more fluorine or chlorine atom(s) or hydroxyl group(s);

R 1 represents a hydroxyl group, C 1 -C 6 alkoxy, NHCN, —NH(C 1 -C 6 alkyl), —NH(C 3 -C 6 cycloalkyl), —NH(aryl), or —O(C 1 -C 6 alkyldiyl)O(C═O)R 11 ; R 11 is a C 1 -C 6 alkyl group which is optionally substituted with one or more fluorine or chlorine atom(s); or a C 3 -C 6 cycloalkyl group which is optionally substituted with one or more fluorine or chlorine atom(s) or hydroxyl group(s);

R 2 represents —NHR 3 ; —NR 20 R 21 ; —OR 22 ; —(OCH 2 —CH 2 ) i —R 23 ; —C 3 -C 10 -heterocyclyl optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl group, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, and oxo; —(Xaa) o ; a mono-, or disaccharide, or a derivative thereof, which is joined to —C(O) by an ester bond via the 1-O, 3-O-, or 6-O-position of the saccharide;

or is selected from the group consisting of:

wherein

R 3 represents (SO 2 R 30 ); (OR 31 ); —C 1 -C 6 alkanediyl(SO 2 R 32 ); —C 1 -C 6 alkanediyl(CO 2 H), an aryl group, a heteroaryl group, a cycloalkyl group or a heterocycloalkyl group, wherein the aryl group is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 )dialkyl, and —C(═O)OR 51 ; wherein the heteroaryl group, is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 )dialkyl and —C(═O)OR 51 ; where the cycloalkyl group is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 )dialkyl, and —C(═O)OR 51 ; and wherein the heterocycloalkyl group is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 )dialkyl and —C(═O)OR 51 ;

R 30 is a C 1 -C 6 alkyl, or an aryl group, wherein the C 1 -C 6 alkyl group is optionally substituted with —NH2, —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, C 1 -C 6 alkylcarbonyloxy-, C 1 -C 6 alkoxycarbonyloxy-, C 1 -C 6 alkylcarbonylthio-, C 1 -C 6 alkylaminocarbonyl-, di(C 1 -C 6 )alkylaminocarbonyl-, one, two or three fluorine or chlorine atoms, or a hydroxyl group;

and wherein the aryl group is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), and —N(C 1 -C 6 )dialkyl;

R 31 is a C 1 -C 6 alkyl group which is optionally substituted with one or more fluorine or chlorine atom(s) or hydroxyl group(s); or a C 3 -C 6 cycloalkyl group which is optionally substituted with one or more fluorine or chlorine atom(s) or hydroxyl group(s);

R 32 is a C 1 -C 6 alkyl group which is optionally substituted with one or more fluorine or chlorine atom(s) or hydroxyl group(s); or a C 3 -C 6 cycloalkyl group which is optionally substituted with one or more fluorine or chlorine atom(s) or hydroxyl group(s);

R 20 and R 21 each independently represents a hydrogen atom; a C 1 -C 6 alkyl group which may be substituted with one or more fluorine or chlorine atom(s) or hydroxyl group(s); a C 3 -C 6 cycloalkyl group which may be substituted with one or more fluorine or chlorine atom(s) or hydroxyl group(s); —C 1 -C 6 alkyldiyl(CO 2 H) or together form a C 3 -C 10 -heterocycloalkyl which may be substituted with one or more C 1 -C 6 alkyl group(s), C 1 -C 6 alkoxy group(s), fluorine or chlorine atom(s) or hydroxyl group(s);

R 22 is a hydrogen atom, a C 1 -C 6 alkyl group; or a C 3 -C 6 cycloalkyl group; wherein the C 1 -C 6 alkyl group or the C 3 -C 6 cycloalkyl group is optionally substituted with —NH2, —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, —NH(C 1 -C 6 )alkyldiyl-C 1 -C 6 alkoxy, one, two or three fluorine or chlorine atom(s), hydroxyl, or C 1 -C 6 alkoxy, an aralkyl group, a heteroalkyl group or a heteroalkylcycloalkyl group;

R 23 is —OH, —O(C 1 -C 3 )alkyl, or —N(C 1 -C 3 )dialkyl;

i is an integer of from 1 to 10;

R 24 , R 25 , and R 26 each independently represents a hydrogen atom; —C(═O)C 11 -C 21 alkyl; or

—C(═O)C 11 -C 21 alkenyl;

R 27 represents —OH; —O(CH 2 ) 2 NH 2 , —OCH 2 —[CH(NH 2 )(CO 2 H)], —O(CH 2 ) 2 N(CH 3 ) 3 ; or

Xaa represents Gly, a conventional D,L-, D- or L-amino acid, a non-conventional D,L-, D- or L-amino acid, or a 2- to 10-mer peptide; and is joined to —C(═O) by an amide bond;

o is an integer of from 1 to 10;

R 4 is selected from the group consisting of:

h is 0, 1, or 2;

R 5 represents a hydrogen atom; a fluorine or chlorine atom; —CF 3 ; —C(═O)OR 51 ;

—NHC(═O)R 52 ; —C(═O)NR 53 R 54 ; or —S(O 2 )OH;

R 51 represents a hydrogen atom; a C 1 -C 6 alkyl group; or a C 3 -C 6 cycloalkyl group; wherein the C 1 -C 6 alkyl group or the C 3 -C 6 cycloalkyl group is optionally substituted with —NH 2 , NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, —NH(C 1 -C 6 )alkyldiyl-C 1 -C 6 alkoxy, one, two or three fluorine or chlorine atom(s), hydroxyl, or C 1 -C 6 alkoxy;

R 52 , R 53 and R 54 each independently represents a C 1 -C 6 alkyl group which is optionally substituted with one or more fluorine or chlorine atom(s); a C 3 -C 6 cycloalkyl group which is optionally substituted with one or more fluorine or chlorine atom(s); or an aryl group which is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 )dialkyl, and an oxo substituent;

R 6 and R 7 each independently represents a hydroxyl group; an —O(C 1 -C 6 )alkyl group, an —O(C 2 -C 6 )alkenyl group, a, —O(C 1 -C 6 )alkyldiylO(C═O)(C 1 -C 6 )alkyl group, or a —O(C 1 -C 6 )alkyldiylO(C═O)(C 2 -C 6 )alkenyl group; wherein the C 1 -C 6 alkyl group and the C 2 -C 6 alkenyl group may be substituted with NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, C 1 -C 6 alkylcarbonyloxy-, C 1 -C 6 alkoxycarbonyloxy-, C 1 -C 6 alkylcarbonylthio-, C 1 -C 6 alkylaminocarbonyl-, di(C 1 -C 6 )alkylaminocarbonyl-, or one, two or three fluorine or chlorine atom(s); or

R 6 represents a hydroxyl group and R 7 represents a group:

R 9 represents C 1 -C 6 alkyl, or aryl; wherein the C 1 -C 6 alkyl is optionally substituted with —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, —NH(C 1 -C 6 )alkyldiyl-C 1 -C 6 alkoxy, one, two or three fluorine or chlorine atom(s), hydroxy, C 1 -C 6 alkoxy, aryl, aryloxy, —C(═O)-aryl, —C(═O)C 1 -C 6 alkoxy; and wherein the aryl group is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, NH(C 1 -C 6 alkyl),

—N(C 1 -C 6 )dialkyl, and an oxo substituent;

g is 1 or 2;

X 1 represents an oxygen atom; sulfur atom; or NH;

X 2 represents an oxygen atom; sulfur atom; NH; or N(CH 3 );

X 3 represents an oxygen atom; sulfur atom; nitrogen atom; carbon atom; or C—OH; and the dashed line represents a carbon-carbon bond or a carbon-carbon double bond;

E is a group represented by the general formula (III) or (IV):

wherein R 12 and R 13 are in cis configuration, and wherein ring A in formula (III) represents a 5-membered or 6-membered carbocyclic or heterocyclic ring containing at least one double bond, including an aromatic carbocyclic or heterocyclic ring, which can be substituted with one to three or one to four substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), and —N(C 1 -C 6 )dialkyl; and L and T each independently represents a ring atom, wherein L and T are adjacent to another;

R 12 and R 13 each independently represents a hydrogen atom, a fluorine atom, hydroxyl, —NH 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, —C(═O)-aryl, —C(═O)C 1 -C 6 alkyl, or —SO 2 (C 1 -C 6 alkyl); or

—SO 2 aryl; wherein any of the foregoing C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or aryl are optionally substituted with one, two or three substituents independently selected from the group consisting of —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, C 1 -C 6 alkylcarbonyloxy-, C 1 -C 6 alkoxycarbonyloxy-, C 1 -C 6 alkylcarbonylthio-, C 1 -C 6 alkylaminocarbonyl-, di(C 1 -C 6 )alkylaminocarbonyl-, fluorine or chlorine atom, and hydroxyl; or R 12 and R 13 are taken together to form a 5-membered or 6-membered ring, which ring is optionally substituted with one, two or three substituents independently selected from the group consisting of —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, C 1 -C 6 alkylcarbonyloxy-, C 1 -C 6 alkoxycarbonyloxy-, C 1 -C 6 alkylcarbonylthio-, C 1 -C 6 alkylaminocarbonyl-, di(C 1 -C 6 )alkylaminocarbonyl-, fluorine or chlorine atom, and hydroxyl;

I is —(CH 2 ) m —Y, wherein

m is an integer of from 3 to 6, provided that m is an integer of from 3 to 5 when E is a group according to general formula (III);

Y represents a group selected from the group consisting of:

wherein

R 40 , R 41 , R 43 , R 44 , R 46 , R 48 and R 49 each independently represents a hydrogen atom, —C 1 -C 6 alkyl, —C 3 -C 6 cycloalkyl, —C 1 -C 6 alkoxy, —C(═O)aryl, or —C(═O)C 1 -C 6 alkyl, wherein any of the foregoing C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, or aryl are optionally substituted with one, two or three substituents independently selected from the group consisting of —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, C 1 -C 6 alkylcarbonyloxy-, C 1 -C 6 alkoxycarbonyloxy-, C 1 -C 6 alkylcarbonylthio-, C 1 -C 6 alkylaminocarbonyl-, di(C 1 -C 6 )alkylaminocarbonyl-, fluorine or chlorine atom, and hydroxy; or R 40 and R 41 , or R 43 and R 44 , are taken together to form a 5-membered or 6-membered ring, which ring may be substituted with one, two or three substituents independently selected from the group consisting of —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, C 1 -C 6 alkylcarbonyloxy-, C 1 -C 6 alkoxycarbonyloxy-, C 1 -C 6 alkylcarbonylthio-, C 1 -C 6 alkylaminocarbonyl-, di(C 1 -C 6 )alkylaminocarbonyl-, fluorine or chlorine atom, and hydroxyl;

R 42 , R 45 , R 47 and R 50 each independently represents a —C 1 -C 3 alkyl, wherein the C 1 -C 3 alkyl may be substituted with one, two or three substituents independently selected from the group consisting of —NH 2 , —NH(C 1 -C 3 )alkyl, —N(C 1 -C 3 )dialkyl, C 1 -C 3 alkylcarbonyloxy-, C 1 -C 3 alkoxycarbonyloxy-, C 1 -C 3 alkylcarbonylthio-, C 1 -C 3 alkylaminocarbonyl-, di(C 1 -C 3 )alkylaminocarbonyl-, fluorine or chlorine atom, and hydroxyl; or R 40 and R 41 ; R 43 and R 44 ; R 49 and R 50 are taken together to form a 5-membered or 6-membered ring, which ring may be substituted with one, two or three substituents independently selected from the group consisting of —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, C 1 -C 6 alkylcarbonyloxy-, C 1 -C 6 alkoxycarbonyloxy-, C 1 -C 6 alkylcarbonylthio-, C 1 -C 6 alkylaminocarbonyl-, di(C 1 -C 6 )alkylaminocarbonyl-, fluorine or chlorine atom, and hydroxyl;

f is an integer of from 0 to 2;

with the proviso that

when X does not comprise a —C(═O)O-motif with the carbonyl carbon in alpha or beta position to the oxygen atom of general formula (II), Y is an oxamide, a carbamate or a carbamide as defined above.

2. The compound according to claim 1 ,

with the further proviso that

when n is 3, 5, 6, 7 or 8, k is 1 and E is a group according to general formula (III) or general formula (IV), wherein each of R 12 and R 13 is a hydrogen atom;

P represents a group:

—(CH 2 ) 3 —O—(CH 2 )—X 81 ; —(CH 2 ) 5 —O—(CH 2 )—X 81 ;

wherein

X 81 represents a group selected from the group consisting of:

R 1′ is defined as R 1 above;

R 2′ represents —NHR 3′ ; —OR 22′ ; —(OCH 2 —CH 2 ) i —R 23 ; a mono-, or disaccharide, or a derivative thereof, which is joined to —C(═O) by an ester bond via the 1-O—, 3-O—, or 6-O-position of the saccharide;

or wherein R 2 is selected from the group consisting of:

wherein

R 3′ represents (SO 2 R 30 ); (OR 31 ); —C 1 -C 6 alkanediyl(SO 2 R 32 ); or —C 2 -C 6 alkanediyl(CO 2 H);

R 22′ is a hydrogen or a C 3 -C 6 cycloalkyl group, which is optionally substituted with —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 )dialkyl, —NH(C 1 -C 6 )alkyldiyl-C 1 -C 6 alkoxy, one, two or three fluorine or chlorine atom(s), hydroxy, or C 1 -C 6 alkoxy;

R 23 and i are as defined above;

R 24 , R 25 , R 26 , and R 27 are as defined above;

R 4′ is defined as R 4 above; and h is defined as above;

R 6′ and R 7′ are defined as R 6 and R 7 above;

R 9′ is defined as R 9 above; R 9″ represents aryl which is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 )dialkyl, and an oxo substituent.

3. The compound according to claim 1 , wherein X is

wherein R 2 is —OR 22 ; —(OCH 2 —CH 2 ) i —R 23 ; a mono-, or disaccharide, or a derivative thereof, which is joined to —C(═O) by an ester bond via the 1-O-, 3-O-, or 6-O-position of the saccharide;

or wherein R 2 is selected from the group consisting of:

wherein R 23 and i are as defined above;

and wherein R 22 , and R 23 to R 27 are as defined in claim 1 .

4. The compound according to claim 1 , wherein X is —C(═O)OH or a salt of the carboxylic acid.

5. The compound according to claim 1 , wherein Y is one of the oxamides defined according to claim 1 .

6. The compound according to claim 1 , wherein X is

wherein R 2 is —OR 22 ; —(OCH 2 —CH 2 ) i —R 23 ; a mono-, or disaccharide, or a derivative thereof, which is joined to —C(═O) by an ester bond via the 1-O-, 3-O-, or 6-O-position of the saccharide;

or wherein R 2 is selected from the group consisting of:

wherein R 22 , R 23 to R 27 and i are as defined in claim 1 , and wherein Y is one of the oxamides defined according to claim 1 .

7. The compound according to claim 1 , wherein X is C(═O)OH, and Y is one of the oxamides defined according to claim 1 .

8. The compound according to claim 1 , with the formula (V):

wherein

R 55 represents —OH; —OR 22 ; —(OCH 2 —CH 2 ) i —R 23 ; a mono-, or disaccharide, or a derivative thereof, which is joined to —C(═O) by an ester bond via the 1-O-, 3-O-, or 6-O-position of the saccharide;

R 22 , R 23 and i are as defined in claim 1 ;

Y represents a group selected from the group consisting of:

wherein R 40 to R 50 are defined in claim 1 ;

R 57 and R 58 are hydrogen; or form together a five- or six-membered ring, preferably an aromatic ring, optionally substituted with one to three or one to four substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, fluorine or chlorine atom, hydroxyl group, amino group, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 )dialkyl, and an oxo substituent;

s is 0, 1 or 2, with the proviso that if s is 0, R 57 and R 58 form together a five- or six-membered ring;

the double bond in formula (V) represents a double carbon-carbon bond in cis-configuration, if R 57 and R 58 are hydrogen, or this double bond is part of a five- or six-membered ring formed together by R 57 and R 58 .

9. The compound according to claim 8 , wherein

R 55 represents —OH or —(OCH 2 —CH 2 ) i —R 23 ; i is 2 to 4;

Y is an oxamide, a carbamide or a carbamate;

R 57 and R 58 are both H, or together form a substituted or non-substituted five- or six-membered aromatic ring; and

s is 1 or s is 0 if R 57 and R 58 together form a substituted or non-substituted five- or six-membered aromatic ring.

10. The compounds according to claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1 , with the formula (VI)

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound according to claim 1 in combination with a physiologically acceptable excipient.

13. A method for the treatment of a cardiovascular disease, comprising the step of administering a compound according to claim 1 to a subject in need thereof in an effective amount.

14. The method according to claim 13 , wherein the cardiovascular disease is selected from the group consisting of atrial fibrillation, atrial tachycardia, ventricular arrhythmia, and heart failure.

15. The method according to claim 13 , wherein the compound or composition is administered orally, topically, subcutaneously, intramuscularly, intraperitoneally, intravenously, intranasally.

16. The method according to claim 13 , wherein the compound or composition is a dosage form selected from the group consisting of a spray, an aerosol, a foam, an inhalant, a powder, a tablet, a capsule, a soft gelatin capsule, a tea, a syrup, a granule, a chewable tablet, a salve, a cream, a gel, a suppository, a lozenge, a liposome composition and a solution for injection.

17. The method according to claim 13 , wherein the cardiovascular disease is selected from the group consisting of atrial fibrillation, ventricular arrhythmia, heart failure, coronary artery disease, myocardial infarction, maladaptive cardiac hypertrophy, and cardiac arrhythmias including ventricular extrasystoles, ventricular tachycardia, malignant ventricular tachycardia, atrial tachycardia, atrial flutter and atrial fibrillation, dilatative cardiomyopathy, and hypertensive heart disease.

18. A method for the treatment of a cardiovascular disease, comprising the step of administering a composition according to claim 12 , to a subject in need thereof in an effective amount.

19. The method according to claim 18 , wherein the cardiovascular disease is selected from the group consisting of atrial fibrillation, ventricular arrhythmia, heart failure, coronary artery disease, myocardial infarction, maladaptive cardiac hypertrophy, and cardiac arrhythmias including ventricular extrasystoles, ventricular tachycardia, malignant ventricular tachycardia, atrial tachycardia, atrial flutter and atrial fibrillation, dilatative cardiomyopathy, and hypertensive heart disease.